EVFM - ネオセティクス （Evofem Biosciences Inc.） ネオセティクスEVFMのチャート
EVFMの企業情報
| symbol | EVFM |
|---|---|
| 会社名 | Evofem Biosciences Inc （ネオセティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Evofem Biosciences Inc formerly Neothetics Inc. is a clinical-stage specialty pharmaceutical company which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is an injectable formulation of the long-acting Beta2-adrenergic receptor agonist and salmeterol xinafoate which is an active ingredient in the United States Food and Drug Administration inhaled products such as SEREVENT DISKUS ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate LIPO-102 an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos or protrusion of the eye from the orbit associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye. ネオセティクスは、米国の製薬会社。審美的な市場のための治療法の開発に従事。局所的な脂肪の減少と体の輪郭に焦点をあて製品の研究開発を行う。非肥満患者の皮下脂肪による中央腹部隆起の縮小のため臨床向けの治療法を開発し、臨床段階の医薬品として、LIPO-202およびLIPO-102を提供する。 |
| 本社所在地 | 12400 High Bluff Drive Suite 600 San Diego CA 92130 USA |
| 代表者氏名 | Saundra Pelletier Saundra Pelletier |
| 代表者役職名 | Chief Executive Officer |
| 電話番号 | +1 858-550-1900 |
| 設立年月日 | 39114 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.evofem.com |
| nasdaq_url | https://www.nasdaq.com/symbol/evfm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -48.26041 |
| 終値（lastsale） | 3.98 |
| 時価総額（marketcap） | 102702407.5 |
| 時価総額 | 時価総額（百万ドル） 100.63800 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 77.85000 |
| 当期純利益 | 当期純利益（百万ドル） -96.53205 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Evofem Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $13.6M to $92.4M. Higher net loss reflects Loss on issuance of Invesco Warrants increase from $0K to $47.9M (expense) Research and development increase of 97% to $12M (expense) General and administrative increase of 73% to $9M (expense). |
EVFMのテクニカル分析
EVFMのニュース
Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021 2021/01/12 14:05:00 Yahoo Finance
Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways.
Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea 2020/12/17 12:00:00 PR Newswire
SAN DIEGO, Dec. 17, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, 'EVOGUARD,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule. EVOGUARD was initiated and the first patient was enrolled in…
Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi® 2020/12/11 13:00:00 PR Newswire
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA)…
Evofem Biosciences (EVFM) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow (NASDAQ:EVFM) 2020/12/02 19:33:27 Seeking Alpha
The following slide deck was published by Evofem Biosciences, Inc. in conjunction with this event..
Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference 2020/11/20 13:30:00 PR Newswire
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020. In advance of the virtual conference and…
Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021 2021/01/12 14:05:00 Yahoo Finance
Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways.
Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea 2020/12/17 12:00:00 PR Newswire
SAN DIEGO, Dec. 17, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, 'EVOGUARD,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule. EVOGUARD was initiated and the first patient was enrolled in…
Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi® 2020/12/11 13:00:00 PR Newswire
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA)…
Evofem Biosciences (EVFM) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow (NASDAQ:EVFM) 2020/12/02 19:33:27 Seeking Alpha
The following slide deck was published by Evofem Biosciences, Inc. in conjunction with this event..
Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference 2020/11/20 13:30:00 PR Newswire
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020. In advance of the virtual conference and…
Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea 2020/12/17 12:00:00 PR Newswire
SAN DIEGO, Dec. 17, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, 'EVOGUARD,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule. EVOGUARD was initiated and the first patient was enrolled in…
Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi® 2020/12/11 13:00:00 PR Newswire
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA)…
Evofem Biosciences (EVFM) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow (NASDAQ:EVFM) 2020/12/02 19:33:27 Seeking Alpha
The following slide deck was published by Evofem Biosciences, Inc. in conjunction with this event..
Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference 2020/11/20 13:30:00 PR Newswire
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020. In advance of the virtual conference and…
Evofem Biosciences to Present at Stifel Virtual Healthcare Conference 2020/11/12 13:30:00 PR Newswire
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET. To access the live and archived webcast of this fireside chat, visit the Investors…